Bromocriptine and CF 25-397 in the Treatment of Tardive Dyskinesia

C. A. Tamminga, T. N. Chase

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Dopamine agonist therapy using se lected drugs at particular dosage levels has been found to have therapeutic benefit in certain dyskinetic syndromes. Two ergot derivatives with dopamine agonist properties were administered at relatively low doses to eight neuroleptic-free schizophrenic patients with tardive dyskinesia. Neither agent significantly improved dyskinetic symptoms; no symptoms worsened. Dopamine agonists likely vary in their selective activation of functionally distinct dopamine receptors.

Original languageEnglish (US)
Pages (from-to)204-205
Number of pages2
JournalArchives of neurology
Issue number4
StatePublished - Apr 1980

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology


Dive into the research topics of 'Bromocriptine and CF 25-397 in the Treatment of Tardive Dyskinesia'. Together they form a unique fingerprint.

Cite this